Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-64304500 add-on therapy in active Crohn's disease
2020-002701-26Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing JNJ-64304500 add-on with Placebo add-on (2 arms). Primary endpoint: Safety and tolerability at Week 12. Started Apr 2021; status: terminated.
02
Drugs
NNC0142-0002
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2020-002701-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002701-26.